New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series
Open Access
- 1 January 2019
- journal article
- editorial
- Published by Elsevier BV in ESMO Open
- Vol. 4 (Suppl 3), e000501
- https://doi.org/10.1136/esmoopen-2019-000501
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- The diverse functions of the PD1 inhibitory pathwayNature Reviews Immunology, 2017
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2017
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals Of Oncology, 2017
- Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell, 2017
- Mechanisms of action and rationale for the use of checkpoint inhibitors in cancerESMO Open, 2017
- Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistanceAnnals Of Oncology, 2016
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic MelanomaJournal of Clinical Oncology, 2015
- Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1Immunotherapy, 2014
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002